Miguel Haime (VA Boston Healthcare System and Boston Medical Center, Boston, USA) is to present an abstract about Somahlution DuraGraft during a rapid response session at the 2016 annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS; 1–5 October, Barcelona, Spain). The abstract is entitled “DuraGraft, a one-time intraoperative treatment for the prevention of vein graft failure improves clinical outcomes after coronary artery bypass grafting – Long-term analysis of 2,436 consecutive patients.”
A press release reports that the study’s objective was to investigate the impact of a novel treatment for intraoperative saphenous vein grafts (DuraGraft treatment) on short and long-term outcomes in patients undergoing coronary artery bypass grafting (CABG). Haime will present the abstract on Tuesday 4th October at 8.47am. He says: “This study truly marks a milestone event in the analysis of graft treatment and patient outcomes. My hope is these important findings presented at EACTS will bring further awareness to the importance of graft treatment and its correlation with clinical outcomes post CABG.”
According to the press release, the acceptance of this abstract is symbolic of the cardiovascular community’s interest in solving the long-standing problem of vein graft disease leading to vein graft failure following bypass surgery. It states that the intraoperative treatment of bypass conduits with DuraGraft, leading to significantly improved outcomes, is a major step forward in addressing this problem.
Satish Chandran, chief executive officer of Somahlution, says: “The presentation at EACTS and the subsequent imminent publication of the VA’s extraordinarily large body of evidence is an important milestone in cardiovascular disease management. This study’s results should help to further establish CABG as the treatment of choice for many with multivessel coronary artery disease.”
